Patient Portal

Brian Van Tine, MD, PhD

Assistant Professor, Medicine
Division of Oncology
Section of Medical Oncology

Specialty Areas

Oncology
Sarcoma
Medical Oncology

Board Certifications

Internal Medicine
Medical Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Medical oncology, cancer, sarcoma, soft tissue sarcoma, bone cancer, leiomyosarcoma, liposarcoma

  • Location(s)
  • Education
  • Publication & Research

Location(s)

Location(s)

Center for Advanced Medicine

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-1171

Education

Education

Medical Degree: University of Alabama at Birmingham 2005
PhD: University of Alabama at Birmingham 2003
Chief Fellow: Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri 2010
BS: University of Arizona, Tucson, Arizona 1995
Residency: Barnes-Jewish Hospital, St. Louis, Missouri 2006
Fellowship: Oncology, Washington University School of Medicine, St. Louis, Missouri 2007

Publication & Research

Publication & Research

Facts and hopes in immunotherapy of soft tissue sarcomas.
Martín-Broto J, Moura DS, Van Tine BA
Clin Cancer Res. 2020 Jun 29; pii: clincanres.3335.2020. doi: 10.1158/1078-0432.CCR-19-3335.

PMID:
    32601077
    [PubMed - as supplied by publisher]
Related citations


Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity.
Baumann BC, Bernstein KA, DeLaney TF, Simone CB 2nd, Kolker JD, Choy E, Levin WP, Weber KL, Muniappan A, Berman AT, Staddon A, Hartner L, Van Tine B, Hirbe A, Glatstein E, Hahn SM, Nagda SN, Chen YL
J Surg Oncol. 2020 Jun 25; doi: 10.1002/jso.26078.

PMID:
    32588468
    [PubMed - as supplied by publisher]
Related citations


Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States.
Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, Chawla SP, Seetharam M, Okuno SH, Bohac C, Chen M, Yurasov S, Attia S
Cancer Med. 2020 Jul; 9(13)4593-4602. doi: 10.1002/cam4.3039.

PMID:
    32374488
    [PubMed - in process]
Related citations


Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL, ANNOUNCE Investigators.
JAMA. 2020 Apr 7; 323(13)1266-1276. doi: 10.1001/jama.2020.1707.

PMID:
    32259228
    [PubMed - indexed for MEDLINE]
Related citations


Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).
Kim A, Lu Y, Okuno SH, Reinke D, Maertens O, Perentesis J, Basu M, Wolters PL, De Raedt T, Chawla S, Chugh R, Van Tine BA, O'Sullivan G, Chen A, Cichowski K, Widemann BC
Sarcoma. 2020; 20205784876. doi: 10.1155/2020/5784876.

PMID:
    32089640
    [PubMed]
Related citations


The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.
Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, Damon AL, Shah S, Kim D, Gómez Tejeda Zañudo J, Hornick JL, Chen YL, Merriam P, Raut CP, Demetri GD, Van Tine BA, Lander ES, Golub TR, Wagle N
Nat Med. 2020 Feb; 26(2)181-187. doi: 10.1038/s41591-019-0749-z.

PMID:
    32042194
    [PubMed - indexed for MEDLINE]
Related citations


Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno SH, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke D, Lazar AJ, Wang WL, Wargo JA, Tawbi HA
Clin Cancer Res. 2020 Mar 15; 26(6)1258-1266. doi: 10.1158/1078-0432.CCR-19-1824.

PMID:
    31900276
    [PubMed - in process]
Related citations


Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
Villalobos VM, Mo G, Agulnik M, Pollack SM, Rushing DA, Singh A, Van Tine BA, McNaughton R, Decker RL, Zhang W, Shahir A, Cronier DM
Cancer Med. 2020 Feb; 9(3)882-893. doi: 10.1002/cam4.2728.

PMID:
    31821732
    [PubMed - in process]
Related citations


Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
Robinson AM, Rathore R, Redlich NJ, Adkins DR, VanArsdale T, Van Tine BA, Michel LS
Cell Death Dis. 2019 Nov 14; 10(11)867. doi: 10.1038/s41419-019-2098-8.

PMID:
    31727874
    [PubMed - in process]
Related citations


Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, Wilky B, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S
J Immunother Cancer. 2019 Oct 24; 7(1)276. doi: 10.1186/s40425-019-0762-2.

PMID:
    31651363
    [PubMed - in process]
Related citations


The Immune Landscape of Cancer.
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Cancer Genome Atlas Research Network., Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I
Immunity. 2019 Aug 20; 51(2)411-412. doi: 10.1016/j.immuni.2019.08.004.

PMID:
    31433971
    [PubMed]
Related citations


Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D, Ley J, Neupane P, Worden F, Sacco AG, Palka K, Grilley-Olson JE, Maggiore R, Salama NN, Trinkaus K, Van Tine BA, Steuer CE, Saba NF, Oppelt P
Lancet Oncol. 2019 Sep; 20(9)1295-1305. doi: 10.1016/S1470-2045(19)30405-X.

PMID:
    31351869
    [PubMed - indexed for MEDLINE]
Related citations


Incidence and Management of Olaratumab Infusion-Related Reactions.
Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD
J Oncol Pract. 2019 Nov; 15(11)e925-e933. doi: 10.1200/JOP.18.00761.

PMID:
    31268811
    [PubMed - in process]
Related citations


Management of localized extremity and retroperitoneal soft tissue sarcoma.
Abaricia S, Van Tine BA
Curr Probl Cancer. 2019 Aug; 43(4)273-282. doi: 10.1016/j.currproblcancer.2019.06.002.

PMID:
    31221500
    [PubMed - in process]
Related citations


Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.
Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM
Cancer Immunol Res. 2019 Aug; 7(8)1237-1243. doi: 10.1158/2326-6066.CIR-18-0940.

PMID:
    31171504
    [PubMed - in process]
Related citations


Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.
Younger E, Ballman K, Lu Y, Pápai Z, Van Tine BA, Attia S, Schöffski P, Reinke D, Tap WD, Jones RL
J Geriatr Oncol. 2020 Apr; 11(3)463-469. doi: 10.1016/j.jgo.2019.05.008.

PMID:
    31126845
    [PubMed - in process]
Related citations


Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Prudner BC, Rathore R, Robinson AM, Godec A, Chang SF, Hawkins WG, Hirbe AC, Van Tine BA
Clin Cancer Res. 2019 Aug 15; 25(16)5122-5134. doi: 10.1158/1078-0432.CCR-19-0206.

PMID:
    31113844
    [PubMed - in process]
Related citations


A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.
Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG
Cancer. 2019 Jul 15; 125(14)2445-2454. doi: 10.1002/cncr.32084.

PMID:
    31034598
    [PubMed - indexed for MEDLINE]
Related citations


A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma.
Van Tine BA, Agulnik M, Olson RD, Walsh GM, Klausner A, Frank NE, Talley TT, Milhem MM
Cancer Med. 2019 Jun; 8(6)2994-3003. doi: 10.1002/cam4.2136.

PMID:
    31016866
    [PubMed - in process]
Related citations


The Metastatic Spine Disease Multidisciplinary Working Group Algorithms.
Wallace AN, Robinson CG, Meyer J, Tran ND, Gangi A, Callstrom MR, Chao ST, Van Tine BA, Morris JM, Bruel BM, Long J, Timmerman RD, Buchowski JM, Jennings JW
Oncologist. 2019 Mar; 24(3)424. doi: 10.1634/theoncologist.2015-0085err.

PMID:
    30867318
    [PubMed]
Related citations

Areas of Research Interest

Our focus is on understanding the genomics of osteosarcoma, leiomyosarcoma and rarer forms of sarcoma. Using mouse genetics, human tumor xenografting and cancer biology we strive to identify druggable targets that can be used in the clinic.